TY - JOUR T1 - First-line Cisplatin Plus Etoposide in High-grade Metastatic Neuroendocrine Tumors of Colon and Rectum (MCRC NET): Review of 8 Cases JF - Anticancer Research JO - Anticancer Res SP - 975 LP - 978 VL - 31 IS - 3 AU - ANNIE PATTA AU - MARWAN FAKIH Y1 - 2011/03/01 UR - http://ar.iiarjournals.org/content/31/3/975.abstract N2 - Background: The combination of cisplatin and etoposide is effective in the treatment of small cell lung carcinomas and other high-grade neuroendocrine tumors (NET). This combination has been considered as a default treatment for patients with high-grade NET of the colon and rectum (CRC). No formal series has yet described the activity of this regimen in this patient population. A retrospective study assessing the efficacy of cisplatin plus etoposide in metastatic CRC (MCRC) NET is reported. Patients and Methods: MCRC NET patients treated with cisplatin and etoposide were identified through the use of pharmacy and tumor registry records from a single institute for the period of 2003-2010. Responses of the identified patients were categorized using RECIST 1.1 (revised response evaluation criteria in solid tumors) guidelines. Results: Eight patients were identified with high-grade CRC NET who had been treated with cisplatin plus etoposide. One patient had a radiographic complete response and four had a partial response. The median progression-free survival was 4.5 months (2-9 months) and the median overall survival was 9.5 months (3.5-17 months). Conclusion: Patients with high-grade CRC NET have a high response rate to cisplatin and etoposide, which in most patients is short-lived, and the survival is limited to less than 1 year. ER -